{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:33:03Z","timestamp":1791473583530,"version":"4.3.4"},"reference-count":38,"publisher":"American Association for Cancer Research (AACR)","issue":"12","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007313","name":"UT | University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P50 CA140388"],"award-info":[{"award-number":["P50 CA140388"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Disease progression following androgen ablation was shown to be associated with upregulation of the glucocorticoid receptor (GR). Longitudinal monitoring of GR expression in circulating extracellular vesicles (EV) may reflect changes in the tumor cell and facilitates detection of acquired resistance. We utilized LNCaP, LREX cells and a patient-derived xenograft, MDA PDX 322-2-6a, for in vitro and in vivo experiments. Plasma-derived EVs were isolated from patients with localized high-risk prostate cancer undergoing androgen ablation. The mRNA levels of GR in EVs and their responsive genes were detected by transcriptome analysis, qRT-PCR and the protein levels by Western blot analysis. We detected changes in GR expression at mRNA and protein levels in EVs derived from LNCaP and LREX cells in in vitro studies. In in vivo experiments, LNCaP and the PDX MDA 322-2-6a\u2013bearing mice were treated with enzalutamide. GR levels in plasma-derived EVs were increased only in those tumors that did not respond to enzalutamide. Treatment of mice bearing enzalutamide-resistant tumors with a GR inhibitor in combination with enzalutamide led to a transient pause in tumor growth in a subset of tumors and decreased GR levels intracellular and in plasma-derived EVs. In a subgroup of patients with high-risk localized prostate cancer treated with androgen signaling inhibition, GR was found upregulated in matching tissue and plasma EVs. These analyses showed that GR levels in plasma-derived EVs may be used for monitoring the transition of GR expression allowing for early detection of resistance to androgen ablation treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Longitudinal monitoring of GR expression in plasma-derived EVs from patients with prostate cancer treated with androgen signaling inhibitors facilitates early detection of acquisition of resistance to androgen receptor signaling inhibition in individual patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0362","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T08:47:50Z","timestamp":1699260470000},"page":"2531-2543","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0332-2385","authenticated-orcid":true,"given":"Emanuela","family":"Gentile","sequence":"first","affiliation":[{"name":"1Department of GU Medical Oncology, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4153-205X","authenticated-orcid":true,"given":"Andrew W.","family":"Hahn","sequence":"additional","affiliation":[{"name":"1Department of GU Medical Oncology, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9252-1468","authenticated-orcid":true,"given":"Jian H.","family":"Song","sequence":"additional","affiliation":[{"name":"1Department of GU Medical Oncology, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2699-4337","authenticated-orcid":true,"given":"Anh","family":"Hoang","sequence":"additional","affiliation":[{"name":"1Department of GU Medical Oncology, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4843-6441","authenticated-orcid":true,"given":"Peter D. A.","family":"Shepherd","sequence":"additional","affiliation":[{"name":"1Department of GU Medical Oncology, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3476-4474","authenticated-orcid":true,"given":"Sumankalai","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"1Department of GU Medical Oncology, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8645-6890","authenticated-orcid":true,"given":"Nora M.","family":"Navone","sequence":"additional","affiliation":[{"name":"1Department of GU Medical Oncology, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6516-0631","authenticated-orcid":true,"given":"Eleni","family":"Efstathiou","sequence":"additional","affiliation":[{"name":"1Department of GU Medical Oncology, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9964-521X","authenticated-orcid":true,"given":"Mark","family":"Titus","sequence":"additional","affiliation":[{"name":"1Department of GU Medical Oncology, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4106-6335","authenticated-orcid":true,"given":"Paul G.","family":"Corn","sequence":"additional","affiliation":[{"name":"1Department of GU Medical Oncology, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6122-4054","authenticated-orcid":true,"given":"Sue-Hwa","family":"Lin","sequence":"additional","affiliation":[{"name":"1Department of GU Medical Oncology, MD Anderson Cancer Center, Houston, Texas."},{"name":"2Department of Translational Molecular Pathology, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6365-1711","authenticated-orcid":true,"given":"Christopher J.","family":"Logothetis","sequence":"additional","affiliation":[{"name":"1Department of GU Medical Oncology, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5754-6950","authenticated-orcid":true,"given":"Theocharis","family":"Panaretakis","sequence":"additional","affiliation":[{"name":"1Department of GU Medical Oncology, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"key":"2023121314030585200_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/gcc.22695","article-title":"Liquid biopsies","volume":"58","author":"Lianidou","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"2023121314030585200_bib2","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell"},{"key":"2023121314030585200_bib3","doi-asserted-by":"crossref","first-page":"679527","DOI":"10.3389\/fcell.2021.679527","article-title":"Emerging role of exosomes in liquid biopsy for monitoring prostate cancer invasion and metastasis","volume":"9","author":"Gao","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2023121314030585200_bib4","first-page":"103","article-title":"Tumor cell-derived exosomes: a message in a bottle","volume":"1826","author":"Kharaziha","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"2023121314030585200_bib5","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2016-05-715961","article-title":"Caspase-3-dependent cleavage of Bcl-xL in the stroma exosomes is required for their uptake by hematological malignant cells","volume":"128","author":"Vardaki","year":"2016","journal-title":"Blood"},{"key":"2023121314030585200_bib6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1080\/10409238.2018.1508276","article-title":"Exosomes at a glance - common nominators for cancer hallmarks and novel diagnosis tools","volume":"53","author":"Gulei","year":"2018","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"2023121314030585200_bib7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/10408363.2014.896316","article-title":"Circulating tumor cells as promising novel biomarkers in solid cancers","volume":"51","author":"Lianidou","year":"2014","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2023121314030585200_bib8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-cellbio-101512-122326","article-title":"Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles","volume":"30","author":"Colombo","year":"2014","journal-title":"Annu Rev Cell Dev Biol"},{"key":"2023121314030585200_bib9","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1158\/1078-0432.CCR-20-4790","article-title":"Radium-223 treatment increases immune checkpoint expression in extracellular vesicles from the metastatic prostate cancer bone microenvironment","volume":"27","author":"Vardaki","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2023121314030585200_bib10","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.eururo.2016.08.012","article-title":"The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients","volume":"71","author":"Del Re","year":"2017","journal-title":"Eur Urol"},{"key":"2023121314030585200_bib11","doi-asserted-by":"crossref","first-page":"10765","DOI":"10.1093\/nar\/gks888","article-title":"Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions","volume":"40","author":"Decker","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"2023121314030585200_bib12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1158\/1078-0432.CCR-17-0989","article-title":"The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved antiandrogen therapy","volume":"24","author":"Puhr","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2023121314030585200_bib13","first-page":"6235","article-title":"Mifepristone has limited activity to enhance the in vivo efficacy of docetaxel and enzalutamide against bone metastatic and castration-resistant prostate cancer","volume":"37","author":"Yang","year":"2017","journal-title":"Anticancer Res"},{"key":"2023121314030585200_bib14","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.molonc.2016.05.001","article-title":"Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors","volume":"10","author":"Zhang","year":"2016","journal-title":"Mol Oncol"},{"key":"2023121314030585200_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12935-018-0683-z","article-title":"Mifepristone inhibits non-small cell lung carcinoma cellular escape from DNA damaging cisplatin","volume":"18","author":"Kapperman","year":"2018","journal-title":"Cancer Cell Int"},{"key":"2023121314030585200_bib16","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.annonc.2021.01.074","article-title":"Exosome-based liquid biopsies in cancer: opportunities and challenges","volume":"32","author":"Yu","year":"2021","journal-title":"Ann Oncol"},{"key":"2023121314030585200_bib17","doi-asserted-by":"crossref","first-page":"011503","DOI":"10.1063\/1.5087122","article-title":"Challenges and opportunities in exosome research-perspectives from biology, engineering, and cancer therapy","volume":"3","author":"Li","year":"2019","journal-title":"APL Bioeng"},{"key":"2023121314030585200_bib18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.7150\/thno.18133","article-title":"Progress in exosome isolation techniques","volume":"7","author":"Li","year":"2017","journal-title":"Theranostics"},{"key":"2023121314030585200_bib19","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/j.apsb.2021.01.001","article-title":"The biology, function, and applications of exosomes in cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"2023121314030585200_bib20","doi-asserted-by":"crossref","first-page":"22519","DOI":"10.1038\/srep22519","article-title":"Cells release subpopulations of exosomes with distinct molecular and biological properties","volume":"6","author":"Willms","year":"2016","journal-title":"Sci Rep"},{"key":"2023121314030585200_bib21","doi-asserted-by":"crossref","first-page":"6360","DOI":"10.1158\/0008-5472.CAN-11-0362","article-title":"Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer","volume":"71","author":"Pan","year":"2011","journal-title":"Cancer Res"},{"key":"2023121314030585200_bib22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0090-4295(02)01741-7","article-title":"Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review","volume":"60","author":"Fakih","year":"2002","journal-title":"Urology"},{"key":"2023121314030585200_bib23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12672-014-0173-2","article-title":"Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer","volume":"5","author":"Isikbay","year":"2014","journal-title":"Horm Cancer"},{"key":"2023121314030585200_bib24","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3389\/fimmu.2019.01545","article-title":"A general introduction to glucocorticoid biology","volume":"10","author":"Timmermans","year":"2019","journal-title":"Front Immunol"},{"key":"2023121314030585200_bib25","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-12-2350","article-title":"FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells","volume":"73","author":"Sahu","year":"2013","journal-title":"Cancer Res"},{"key":"2023121314030585200_bib26","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/med.21311","article-title":"The unique pharmacological characteristics of mifepristone (RU486): from terminating pregnancy to preventing cancer metastasis","volume":"34","author":"Chen","year":"2014","journal-title":"Med Res Rev"},{"key":"2023121314030585200_bib27","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1464-410X.2008.07509.x","article-title":"A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones","volume":"101","author":"Taplin","year":"2008","journal-title":"BJU Int"},{"key":"2023121314030585200_bib28","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1158\/1078-0432.CCR-21-4049","article-title":"Phase I\/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer","volume":"28","author":"Serritella","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2023121314030585200_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat Rev Urol"},{"key":"2023121314030585200_bib30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.semcancer.2021.11.001","article-title":"Understanding and targeting prostate cancer cell heterogeneity and plasticity","volume":"82","author":"Tang","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"2023121314030585200_bib31","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nm.3915","article-title":"Toward understanding and exploiting tumor heterogeneity","volume":"21","author":"Alizadeh","year":"2015","journal-title":"Nat Med"},{"key":"2023121314030585200_bib32","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.eururo.2014.04.014","article-title":"Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications","volume":"67","author":"Gerlinger","year":"2015","journal-title":"Eur Urol"},{"key":"2023121314030585200_bib33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrclinonc.2016.76","article-title":"Tomlins SA. Translational and clinical implications of the genetic landscape of prostate cancer","volume":"13","author":"Spratt","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"2023121314030585200_bib34","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.humpath.2010.02.011","article-title":"Multifocal prostate cancer: biologic, prognostic, and therapeutic implications","volume":"41","author":"Andreoiu","year":"2010","journal-title":"Hum Pathol"},{"key":"2023121314030585200_bib35","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1158\/1541-7786.MCR-09-0072","article-title":"Expression of PGK1 by prostate cancer cells induces bone formation","volume":"7","author":"Jung","year":"2009","journal-title":"Mol Cancer Res"},{"key":"2023121314030585200_bib36","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1038\/s41388-021-01754-0","article-title":"Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer","volume":"40","author":"Puhr","year":"2021","journal-title":"Oncogene"},{"key":"2023121314030585200_bib37","doi-asserted-by":"crossref","first-page":"696","DOI":"10.7150\/jca.32497","article-title":"Emerging role of glucocorticoid receptor in castration resistant prostate cancer: a potential therapeutic target","volume":"11","author":"Kumar","year":"2020","journal-title":"J Cancer"},{"key":"2023121314030585200_bib38","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3390\/cancers13071649","article-title":"Prognostic significance of glucocorticoid receptor expression in cancer: a systematic review and meta-analysis","volume":"13","author":"Bakour","year":"2021","journal-title":"Cancers"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0362\/3380719\/crc-23-0362.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/12\/2531\/3390855\/crc-23-0362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/12\/2531\/3390855\/crc-23-0362.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T09:03:53Z","timestamp":1702458233000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/12\/2531\/731697\/Monitoring-Glucocorticoid-Receptor-in-Plasma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,13]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0362","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.24799610","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799622","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799628","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799604","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799616","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799628.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799631.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799625.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799622.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799631","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799601","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799613.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799607","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799619","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799613","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799625","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799619.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799616.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799610.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799604.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799607.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24799601.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6978761.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6978761","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,13]]}}}